CDH1 and prostate carcinoma: Further similar results were observed when cancer cells were treated with β-catenin siRNA; apigenin exposure in DU145 prostate cancer cells increased E-cadherin protein expression, prevented nuclear movement of β-catenin and its accumulation in the cytoplasm, and declined c-Myc and cyclin D1 levels.